Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Matsui, Hideto ^a   Fujimoto, Naoko ^b,c   Sasakawa, Noriko ^b   Ohinata, Yasuhide ^d,e   Shima, Midori ^a   Yamanaka, Shinya ^b,c,f   Sugimoto, Mitsuhiko ^a   Hotta, Akitsu ^b,c,e  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF YAMANASHI   (Japan)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^f GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; COMPLEMENTARY DNA; TRANSPOSON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; BLOOD CLOTTING TIME; CONTROLLED STUDY; DNA EXTRACTION; GENE VECTOR; HEMOPHILIA A; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHENOTYPE; PHENOTYPIC VARIATION; PIGGYBAC TRANSPOSON VECTOR; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TRANSGENE; TRANSPOSON; ADMINISTRATION AND DOSAGE; ANIMAL; BLOOD; DISEASE MODEL; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETICS; HEK293 CELL LINE; MOUSE; PROCEDURES; THERAPEUTIC USE;

ANIMALS; DISEASE MODELS, ANIMAL; DNA TRANSPOSABLE ELEMENTS; DNA, COMPLEMENTARY; FACTOR VIII; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HEMOPHILIA A; HUMANS; MICE;

EID: 84920853211     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104957     Document Type: Article

References (43)

1. Mátrai J, Chuah MKL, Vandendriessche T (2010) Preclinical and clinical progress in hemophilia gene therapy. Curr Opin Hematol. pp. 387-392.
2. Brown BD, Shi CX, Powell S, Hurlbut D, Graham FL, et al. (2004) Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood. pp. 804-810. (Pubitemid 38129536)
3. Hu C, Cela RG, Suzuki M, Lee B, Lipshutz GS (2011) Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII. Proc Natl Acad Sci USA. pp. 2082-2087.
4. Sarkar R, Tetreault R, Gao G, Wang L, Bell P, et al. (2004) Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood 103: 1253-1260. (Pubitemid 38168635)
5. Jiang H, Lillicrap D, Patarroyo-White S, Liu T, Qian X, et al. (2006) Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108: 107-115. (Pubitemid 43990618)
6. Lu H, Chen L, Wang J, Huack B, Sarkar R, et al. (2008) Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette. Hum Gene Ther. pp. 648-654. (Pubitemid 351913523)
7. Powell JS, Ragni MV, White GC, Lusher JM, Hillman-Wiseman C, et al. (2003) Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood. pp. 2038-2045. (Pubitemid 37122377)
8. Kootstra NA, Matsumura R, Verma IM (2003) Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol Ther. pp. 623-631. (Pubitemid 36626242)
9. Kang Y, Xie L, Tran DT, Stein CS, Hickey M, et al. (2005) Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood. pp. 1552-1558. (Pubitemid 41208565)
10. Matsui H, Hegadorn C, Ozelo M, Burnett E, Tuttle A, et al. (2011) A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A. Mol Ther. pp. 723-730.
11. Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, et al. (2007) Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells. pp. 2660-2669. (Pubitemid 47582759)
12. Tatsumi K, Sugimoto M, Lillicrap D, Shima M, Ohashi K, et al. (2013) A Novel Cell-Sheet Technology That Achieves Durable Factor VIII Delivery in a Mouse Model of Hemophilia A. PLoS ONE: Public Library of Science. pp. e83280.
13. Liras A, Olmedillas S (2009) Gene therapy for haemophilia...yes, but...with non-viral vectors? Haemophilia. pp. 811-816.
14. Thomas CE, Birkett D, Anozie I, Castro MG, Lowenstein PR (2001) Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther 3: 36-46. (Pubitemid 32509803)
15. Pipe SW (2009) Functional roles of the factor VIII B domain. Haemophilia. pp. 1187-1196.
16. Chavez CL, Keravala A, Chu JN, Farruggio AP, Cuéllar VE, et al. (2012) Long-term expression of human coagulation factor VIII in a tolerant mouse model using the QC31 integrase system. Hum Gene Ther. pp. 390-398.
17. Li H, Haurigot V, Doyon Y, Li T, Wong SY, et al. (2011) In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature. pp. 217-221.
18. Ohlfest JR, Frandsen JL, Fritz S, Lobitz PD, Perkinson SG, et al. (2005) Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood. pp. 2691-2698. (Pubitemid 40446258)
19. Thibault ST, Singer MA, Miyazaki WY, Milash B, Dompe NA, et al. (2004) A complementary transposon tool kit for Drosophila melanogaster using P and piggyBac. Nat Genet. pp. 283-287. (Pubitemid 38282754)
20. Ding S, Wu X, Li G, Han M, Zhuang Y, et al. (2005) Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell. pp. 473-483. (Pubitemid 41127147)
21. Wilson MH, Coates CJ, George AL (2007) PiggyBac transposon-mediated gene transfer in human cells. Mol Ther.pp. 139-145. (Pubitemid 46043659)
22. Huang X, Guo H, Tammana S, Jung Y-C, Mellgren E, et al. (2010) Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells. Mol Ther. pp. 1803-1813.
23. Li MA, Turner DJ, Ning Z, Yusa K, Liang Q, et al. (2011) Mobilization of giant piggyBac transposons in the mouse genome. Nucleic Acids Res. pp. e148.
24. Doherty JE, Huye LE, Yusa K, Zhou L, Craig NL, et al. (2012) Hyperactive piggyBac gene transfer in human cells and in vivo. Hum Gene Ther. pp. 311-320.
25. Hotta A, Cheung AYL, Farra N, Vijayaragavan K, Séguin CA, et al. (2009) Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nat Methods. pp. 370-376.
26. Yusa K, Zhou L, Li MA, Bradley A, Craig NL (2011) A hyperactive piggyBac transposase for mammalian applications. Proc Natl Acad Sci USA. pp. 1531-1536.
27. Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
28. Lind P, Larsson K, Spira J, Sydow-Backman M, Almstedt A, et al. (1995) Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization. Eur J Biochem 232: 19-27.
29. Barrow RT, Healey JF, Jacquemin MG, Saint-Remy JM, Lollar P (2001) Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood 97: 169-174. (Pubitemid 32061257)
30. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872. (Pubitemid 350138099)
31. Liu F, Song Y, Liu D (1999) Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. pp. 1258-1266. (Pubitemid 29359019)
32. Kamisue S, Shima M, Nishimura T, Tanaka I, Nakai H, et al. (1994) Abnormal factor VIII Hiroshima: defect in crucial proteolytic cleavage by thrombin at Arg1689 detected by a novel ELISA. Br J Haematol. pp. 106-111. (Pubitemid 24194388)
33. Nakanishi H, Higuchi Y, Kawakami S, Yamashita F, Hashida M (2010) piggyBac transposon-mediated long-term gene expression in mice. Mol Ther. pp. 707-714.
34. Yamanaka S (2009) A fresh look at iPS cells. Cell 137: 13-17.
35. Petrus I, Chuah M, Vandendriessche T (2010) Gene therapy strategies for hemophilia: benefits versus risks. J Gene Med. pp. 797-809.
36. Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, et al. (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. pp. 2357-2365.
37. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, et al. (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. pp. 401-409.
38. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. pp. 415-419. (Pubitemid 37296260)
39. Cesana D, Ranzani M, Volpin M, Bartholomae C, Duros C, et al. (2014) Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther.
40. Kamimura K, Suda T, Xu W, Zhang G, Liu D (2009) Image-guided, lobe-specific hydrodynamic gene delivery to swine liver. Mol Ther. pp. 491-499.
41. Suda T, Suda K, Liu D (2008) Computer-assisted hydrodynamic gene delivery. Mol Ther. pp. 1098-1104. (Pubitemid 351737075)
42. Hackett PB Jr, Aronovich EL, Hunter D, Urness M, Bell JB, et al. (2011) Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. Curr Gene Ther 11: 341-349.
43. Reddy LH, Couvreur P (2011) Nanotechnology for therapy and imaging of liver diseases. J Hepatol 55: 1461-1466.